about
Markedly inhibited 7-dehydrocholesterol-delta 7-reductase activity in liver microsomes from Smith-Lemli-Opitz homozygotesSterols and oxysterols in plasma from Smith-Lemli-Opitz syndrome patientsPlasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liverAbsence of Nceh1 augments 25-hydroxycholesterol-induced ER stress and apoptosis in macrophagesSmall-bowel mucosal injuries in low-dose aspirin users with obscure gastrointestinal bleeding.Serum carnitine as an independent biomarker of malnutrition in patients with impaired oral intakeCholestenoic acids regulate motor neuron survival via liver X receptors.Simultaneous quantification of salivary 3-hydroxybutyrate, 3-hydroxyisobutyrate, 3-hydroxy-3-methylbutyrate, and 2-hydroxybutyrate as possible markers of amino acid and fatty acid catabolic pathways by LC-ESI-MS/MS.Dehydroepiandrosterone and its derivatives: potentially novel anti-proliferative and chemopreventive agents.Retention of acetylcarnitine in chronic kidney disease causes insulin resistance in skeletal muscleCholesterol and chronic hepatitis C virus infection.Increased N-acetyltaurine in serum and urine after endurance exercise in human.The role of taurine on skeletal muscle cell differentiation.Cholesterol 25-hydroxylation activity of CYP3A.Hypercholesterolemia in rats with hepatomas: increased oxysterols accelerate efflux but do not inhibit biosynthesis of cholesterol.Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines.Human intestinal spirochaetosis in two ulcerative colitis patients.Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection.Highly sensitive quantification of serum malonate, a possible marker for de novo lipogenesis, by LC-ESI-MS/MS.Bile acid flux through portal but not peripheral veins inhibits CYP7A1 expression without involvement of ileal FGF19 in rabbits.A SNP of NPC1L1 affects cholesterol absorption in Japanese.Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy.Clinical features of gastroduodenal ulcer in Japanese patients taking low-dose aspirin.Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27-/- mice but not in cerebrotendinous xanthomatosis.Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines.Dietary cholesterol stimulates CYP7A1 in rats because farnesoid X receptor is not activated.Simultaneous determination of dehydroepiandrosterone and its 7-oxygenated metabolites in human serum by high-resolution gas chromatography--mass spectrometry.Assessment of tear concentrations on therapeutic drug monitoring. III. Determination of theophylline in tears by gas chromatography/mass spectrometry with electron ionization mode.The associated markers and their limitations for the primary screening of HCV carriers in public health examination.The protective effect of taurine against hepatic damage in a model of liver disease and hepatic stellate cells.Serum concentration of 27-hydroxycholesterol predicts the effects of high-cholesterol diet on plasma LDL cholesterol level.Agaro-Oligosaccharides Regulate Gut Microbiota and Adipose Tissue Accumulation in Mice.Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS.Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS.The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.Stigmasterol reduces plasma cholesterol levels and inhibits hepatic synthesis and intestinal absorption in the rat.Reciprocal interactions between bile acids and gut microbiota in human liver diseases.Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease.Circulating tricarboxylic acid cycle metabolite levels in citrin-deficient children with metabolic adaptation, with and without sodium pyruvate treatment.Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic HCV Infection: A Possible Impact on the Efficacy and Safety of IFN-free Treatment.
P50
Q24678423-049FB3B7-3557-4131-97FE-7C5B713A1875Q26765783-FC7D9447-2912-41F8-988C-9CD7AFD54A9CQ28258554-9101BA45-7F4D-4A41-BDDE-C584EAD6448DQ34238679-0D11C208-2242-48B6-A8A0-506A394A4EE1Q34255548-966618C1-4F11-4A47-8C54-6EEA79029234Q34489986-FAE8AEED-D067-4242-9046-BD9F90F6EF5BQ35140077-DC863295-88BA-43A4-85C6-67E3F9A00DD8Q36062956-55EAE640-66E7-4CB5-9721-C0BA78458B52Q36612051-348DBA9D-4AD7-4B16-8797-C8884DFDBFA7Q37416560-3205C64E-1845-4E75-9DC2-11970617CDBAQ37891171-A5136DD2-EFB6-4297-9CDE-7C336A1F60BCQ38891788-061D4012-0274-4957-B5EB-BD8E361619ABQ39197695-2C996CE9-D9A8-4366-B638-E9DD519EB48BQ39541370-FB20E558-2AAD-44DE-99F3-4C73B5E50E1BQ40238093-C4EFBF18-32F6-4B65-8CDC-38DB8CBFCB25Q40391291-5B8C5CDF-D13D-4296-8554-2F805B81F44EQ41738398-696E8B92-9A53-46C1-8EF6-9DAE04FEB3F0Q42237257-E8ABECF6-4D54-4C2F-AE5A-0403B403B016Q42549065-6BCC001C-593F-4D3D-97D1-DEA7BA6AE5CEQ42704943-3564BAD7-A691-4D20-B2B2-6501AEA3DED2Q43105482-B8ACD06E-C490-4BCD-9005-AF9BF08564D4Q43216541-44CB6E4A-8D8A-4664-8132-FFFE35E6F13FQ43236092-CC40766F-F949-4027-87AE-0B42696771E4Q43675409-6BB74698-30DF-4320-9F0C-5686237CEB9FQ44244689-4FA650E9-B6B9-448A-8F50-28102F837C1CQ44698743-668514C8-8F30-4260-B62D-A93283649357Q45176161-A213F275-4135-4A1E-AE0B-6D3DD5B20888Q45201248-773B4326-FE25-41B8-830C-7B2DF2FE95BEQ46005698-0DBA7473-5856-49E5-9705-7A0D4310C8F5Q46111185-3CB33CBD-A96C-429D-9F10-A38BFF0354B6Q46126236-14990023-6A30-46C1-A689-145AAA85D258Q46294662-B9532AFA-0349-476F-B0D1-F26D2B32FA46Q46348618-8CC2955E-C376-4688-A01D-1ED40F1F3E66Q46575684-F1C4A558-F2BB-4D38-AFBA-8B22709DBE4AQ46900648-962DEC42-0C78-4049-A8CA-686023462BF7Q46948981-B777FDBB-CC68-484A-9EDE-C08237B54E1FQ47389652-09601AA6-DC62-4DEC-9D9E-76C813D7EDF8Q47791527-CFA7906A-345A-4E0A-BED9-CCAE13D009D2Q48375914-B29E8F89-0887-4D38-9027-0007963CB870Q49567497-29DFBF1A-45B5-401E-AAC4-AF9654C432B2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Akira Honda
@ast
Akira Honda
@en
Akira Honda
@es
Akira Honda
@nl
Akira Honda
@sl
type
label
Akira Honda
@ast
Akira Honda
@en
Akira Honda
@es
Akira Honda
@nl
Akira Honda
@sl
prefLabel
Akira Honda
@ast
Akira Honda
@en
Akira Honda
@es
Akira Honda
@nl
Akira Honda
@sl
P106
P1153
57200721754
7103189057
P21
P31
P496
0000-0003-0902-8272